Home Pfizer

Pfizer

Random

Pfizer

Pfizer, BioNTech COVID-19 Vaccine >90% Effective in Early Phase III Data

Gastrointestinal Disorders

Inflection Point: Abivax Challenges Pharma Giants in Ulcerative Colitis

Pfizer

Pfizer, Sangamo Report Positive Phase I/II Data for Severe Hemophilia A Gene Therapy

Pfizer

Quartet of COVID-19 Vaccine Candidates Head toward the Homestretch

Pfizer

Pfizer to Develop Akcea/Ionis Antisense Candidate for Up to $1.5B

Pfizer

Pfizer to Acquire Trillium for $2.3B, Boosting Cancer Pipeline

Gene Therapy

FDA Lifts Clinical Hold on Pfizer DMD Gene Therapy Linked to...

Pfizer

Sangamo CEO Ponders Pipeline, Reflects on Phase III ‘Proud Moment’

Pfizer

FDA Grants Pfizer, BioNTech Emergency Use Authorization for COVID-19 Vaccine

Pfizer

Pfizer, BioNTech Plan Clinical Trial for COVID-19 mRNA Vaccine Candidate

Blood Disorders

Pfizer to Acquire GBT for $5.4B, Adding Sickle Cell Disease Drug...

Pfizer

Quartet of COVID-19 Vaccine Candidates Head toward the Homestretch

Pfizer

Pfizer, BioNTech Report 95% Final Efficacy for COVID-19 Vaccine

Coronavirus

“Game Changer:” After Vaccines, Pfizer Stakes Claim in COVID-19 Drugs, Too

Gastrointestinal Disorders

Inflection Point: Abivax Challenges Pharma Giants in Ulcerative Colitis

12 3 Page 1 of 3